RXST vs. BHC, EDAP, CLPT, STIM, APYX, BLCO, STAA, WRBY, EYE, and LUCY
Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Bausch Health Companies (BHC), Edap Tms (EDAP), ClearPoint Neuro (CLPT), Neuronetics (STIM), Apyx Medical (APYX), Bausch + Lomb (BLCO), STAAR Surgical (STAA), Warby Parker (WRBY), National Vision (EYE), and Innovative Eyewear (LUCY). These companies are all part of the "medical" sector.
RxSight (NASDAQ:RXST) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
RxSight has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
78.8% of RxSight shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are held by institutional investors. 9.4% of RxSight shares are held by company insiders. Comparatively, 8.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Bausch Health Companies received 315 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
RxSight has higher earnings, but lower revenue than Bausch Health Companies. RxSight is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
In the previous week, RxSight had 3 more articles in the media than Bausch Health Companies. MarketBeat recorded 4 mentions for RxSight and 1 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 1.78 beat RxSight's score of 0.34 indicating that Bausch Health Companies is being referred to more favorably in the news media.
RxSight presently has a consensus target price of $60.63, suggesting a potential upside of 3.74%. Bausch Health Companies has a consensus target price of $11.33, suggesting a potential upside of 77.36%. Given Bausch Health Companies' higher probable upside, analysts plainly believe Bausch Health Companies is more favorable than RxSight.
Bausch Health Companies has a net margin of -5.07% compared to RxSight's net margin of -44.01%. RxSight's return on equity of -27.68% beat Bausch Health Companies' return on equity.
Summary
RxSight beats Bausch Health Companies on 10 of the 18 factors compared between the two stocks.
Get RxSight News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
